Abstract We have developed a model for economic evaluation related to the diagnostic accuracy (sensitivity and specificity) of near patient tests used in office laboratories, as opposed to using hospital-based tests. Blood-sample based tests to detect the bacterium Helicobacter Pylori (HP) are useful in diagnosing peptic ulcer, and suitable to illustrate the model. First, general practitioners' initial management plans for a dyspeptic patient are elucidated using a paper vignette survey. Based on survey results, and medical literature, a decision tree is constructed to visualize expected costs and outcomes resulting from using three different HP tests. Tests included are two rapid tests for use in general practice, and one hospital laboratory test for comparison. The tests had different sensitivities and specificities. Then a cost-effectiveness analysis is undertaken from a societal perspective. Finally we use sensitivity analyses to model the decision uncertainty. Estimating for a follow-up period of 120 days, the rapid test with lower sensitivity and specificity than the hospital HP test is cost-effective because the test result is available immediately. Further, in general practice, the rapid test with the highest sensitivity is significantly cost effective compared to the test with the highest specificity when the willingness to pay for each dyspepsia-free day exceeds e42.6. When deciding whether a laboratory analysis should be analyzed in the office laboratory or not, it is important to consider both the diagnostic accuracy of the tests and waiting time for the alternative hospital laboratory result.
Introduction
Diagnostic tests and in particular laboratory tests are often important in the diagnostic work-up and monitoring of patients. Therefore the economic consequences of laboratory tests may amount to a substantial proportion of health service costs. Thus, it is of public interest to study the consequences and costs of using such tests as opposed to using hospital-based tests.
Compared with other European countries, e.g., Denmark and England, office laboratory analyses are much more used in Norway in general practice, mainly due to geographical factors and economic incentives. In Norway about 99% (1,900) of all surgeries have office laboratory facilities run by general practitioners (GPs), serving a population of 4.6 million.
Dyspepsia is a fairly common presenting symptom in general practice consultations [1] [2] [3] [4] . Sometimes dyspepsia is due to peptic ulcer, and the bacterium Helicobacter Pylori (HP) has been identified as the main cause of this disease. Thus it is important to be able to detect the bacterium in dyspeptic patients. 1 The presence of antibodies to this bacterium may be detected by a blood sample-based HP rapid test in the GP's office, or by sending a blood sample for serological testing in a larger laboratory (hospital-based test). The rapid test is a simple test kit for single use, just a drop of blood is needed, and the result is read as negative or positive. Since the test is easy to perform, the analytical quality of the test result depends mainly on the diagnostic accuracy (sensitivity and specificity) 2 of the test kit and less on the level of training of the person performing the analysis.
The advantage of having the test available in general practice is that the GP can get the result of the test immediately, during the consultation. In contrast, if the GP sends a blood sample for serological testing, it takes 2-7 days to get the result, and this may delay the treatment and usually demands more follow-up by the GP. In Norway and elsewhere there have been discussions about whether HP rapid tests have sufficient diagnostic accuracy to be used in the office laboratory [7, 8] . Thus we aimed to compare two rapid tests, Immunocard and Helisal, and one hospital-based test, HmCap, taking aspects both of diagnostic accuracy and consequences of delayed test results into account.
There are many laboratory tests available for use in the surgery, and the reasons for choosing the HP analysis were several: it is a fairly new test, it can be carried out both as a rapid test and as an ordinary ''hospital laboratory'' test, it may be a crucial test in that other laboratory tests are usually not needed, and there are more complex procedures or gold standards available to evaluate the benefit (predictive value) of the test.
In Fauli and Thue [9] we found that the result of the HP test had a significant and major influence on the GPs' choice of medical actions when dealing with a young dyspeptic patient, which implies that the diagnostic accuracy of the laboratory analysis is crucial.
Our study has four key components:
• First, a case history-based survey of GPs' management of a patient with dyspepsia was performed, and three strategies for initial handling of these patients based on HP test results were elucidated (symptomatic treatment, upper endoscopy and triple therapy).
• Second, these strategies were implemented in a decision model. The therapeutic decision problem is constructed using principles of clinical decision analysis, where clinical events and costs of relevant strategies are compared using a decision tree [10] .
• Third, the principles of cost-effectiveness analysis are used to compare test alternatives (Immunocard, Helisal, HmCap) in terms of costs and health outcome, based on Gold et al. [11] . The cost-effectiveness analysis is done from a societal perspective.
• Finally we use sensitivity analyses including a probabilistic sensitivity analysis (PSA) to model the decision uncertainty.
Outcome is quantified in terms of ''number of dyspepsia-free days'' after successful treatment, i.e., the expected number of days within a period of 120 days, in which the patient is assumed to be ''cured'' of this episode of dyspepsia. The patient is categorized as cured if she can be assumed to be without dyspeptic symptoms resulting in need for healthcare of any kind.
We are not aware of any other study comparing HP tests focusing on cost-effectiveness from a societal perspective due to variations in diagnostic accuracy and variations in waiting time to receive the laboratory result. There are studies of cost-effectiveness of the management of dyspeptic patients as in Ford et al. [12] , Lassen et al. [13] and Ofman et al. [14] . These studies focus on different treatment strategies (compare ''test and treat'' versus upper endoscopy), and do not study the impact of the variation in diagnostic accuracy of different HP tests. Briggs et al. [15] study the cost-effectiveness of screening for and eradication of HP bacteria. They use an HP test to identify patients with an increased probability of having viable HP bacteria, and found that the sensitivity and specificity of the serology test had an important effect on the effectiveness of the test and treatment strategy. Further, these studies are from the health service perspective. They only include the direct medical costs, but not the indirect costs included in our study: the costs imposed on the patient or the employer.
We assume that the clinical practice of GPs for treating ulcers in Norway is representative of the clinical practice of GPs in other western countries, because pertinent guidelines were easily available to Norwegian GPs, e.g., in the Norwegian textbook of general practice [16] and in an editorial in the Journal of the Norwegian Medical Association [17] .
Thus, the same decision tree can be used in other countries although the absolute and relative costs may well be different. It also seems reasonable to assume that we can use this model for clinical situations in which other diagnostic tests are used as important sources of information, e.g., MRI, X-ray or other laboratory analyses. Hence, our method has interest beyond the setting used in this article.
Methods
This section includes a description of the first and second key components of the study. We used data from a case history-based survey of GPs' management of a 31-year-old female patient with dyspep-sia designed in cooperation with ''The Norwegian Quality Improvement of Laboratory Services in Primary Care'' (NOKLUS). More details on the survey are in Fauli and Thue [9] .
The present analysis focuses on the subgroup of GPs in the survey who decided to use a HP test in the clinical situation described in the case history. We grouped the sets of medical actions based on the medical strategies chosen: symptomatic treatment, (referral for) upper endoscopy or triple therapy. The survey shows that the GPs' choices of medical actions strongly depend on the result of the rapid test. It is therefore crucial that the result is correct.
For GPs using a hospital-based test we only have information on the choices made at the first consultation, before receiving the laboratory result. In the calculations we assume that these GPs choose the same actions as GPs with the rapid test when they receive the laboratory result a few days later. However, their actions may be different up to that point when they receive the test result, as discussed below.
Second key component: the decision model
The decision problem for the GP is which test to use, i.e., in principle to have one of the rapid tests on the market available in the office laboratory, or to rely on a hospitalbased test. Our model therefore is a decision tree with three main branches, one for each test. The branches are mutually exclusive since the GP only uses one test. The structure of the decision tree is based on the main treatment strategies suggested in our survey. We follow the patient from the consultation where it is decided to use the HP test until the patient is cured or until a false laboratory result is detected and treatment is given. The branches for the rapid tests (Immunocard and Helisal) are identical, but with different probabilities for true/false negative/positive, and for simplicity we only present the strategy for Immunocard in Fig. 1 .
Since the case history gives no indication that the patient may have gastroesophageal reflux disease, the patient is assumed to have either ulcer (pre-test prevalence assumed to be 20%) or NUD (non-ulcer or ''functional'' dyspepsia). Other causes of dyspepsia in this age group are considered negligible. From the survey we have information about the choice of medical actions for GPs with rapid tests at the first and second consultations related to whether the result of the HP test at the first consultation is positive or negative. A second consultation is only needed if the patient is not cured after treatment given at first consultation. Our model does not include further follow-up for the fraction (4.5%) of patients assumed not to be cured by the end of the 120-day period.
For GPs using the hospital-based test, we have information on four initial medical strategies chosen before having the result of the test (Fig. 2) . Since the choices made at the first consultation will have consequences for medical strategies and costs when the test result is known, the decision tree has a branch for each strategy chosen at the first consultation. Recall that we have assumed that these GPs choose the same actions as GPs with the rapid tests, thus for each of the four initial medical strategies the rest of the tree structure is identical to the decision tree of the rapid test shown in Fig. 1 . If the GP using a hospital-based test does not want to change the medical strategy after receiving the test result, there will be no time delay or extra cost. If the GP needs to change the medical strategy, there will both be a time delay of 5 days to receive the result of the test and the cost of inefficient actions at the first consultation. In addition, the hospital laboratory result may be followed-up by an extra consultation, and we assume this to be done in 75% of the cases if the laboratory result is positive, and in 25% of the cases if it is negative. The extra consultation gives further delay and extra cost.
If the patient is not cured by the treatment, it is assumed that she will have another consultation with the GP. From the survey we know that the GP then always refers the patient for upper endoscopy. If it is found that the patient has an ulcer, she receives triple therapy, and if the patient has NUD we assume that she receives only further symptomatic treatment. If the patient is not cured after upper endoscopy and triple therapy, we assume a second upper endoscopy will be undertaken inter alia to determine whether another type of antibiotic therapy will be effective.
The probabilities in the decision tree are shown in Tables 1, 2 , and the cost elements are shown in Table 3 . We used ''TreeAge Pro'' [18] for estimating results.
Test-related probabilities in the model Table 1 shows that Helisal has lower sensitivity and specificity than the hospital-based test. With a pre-test prevalence for ulcer of 20%, the fraction of true and false negative/positive test results may be calculated depending on the sensitivity and specificity of the tests studied.
How the health effect is measured Our primary assumption is that if the patient is not cured initially, she will be subject to follow-up including upper endoscopy. We chose a time span of 120 days because it took at most 119.25 days from the first consultation until the actions taken in a follow-up consultation (when necessary) were completed (Fig. 1) .
The effect of actions taken is the ''number of dyspepsiafree days'' after successful treatment, i.e., days with no need for professional health care for dyspeptic symptoms after the patient has finished follow-up and treatment. The limitations of this measure are addressed in the discussion. Both the survey and the Norwegian Pharmaceutical Product Compendium [23] have provided information about the length of different medical strategies; symptomatic treatment-14 days, triple therapy-7 days, and 5 weeks waiting time to have upper endoscopy.
If a new consultation was needed by GPs using the hospital-based test after they received the laboratory result, we assumed the waiting time for this consultation to be 3 days. If the patient was not cured after treatment, we assumed it took on average 1 week after finishing treatment to the next consultation. Table 2 gives an overview of the probabilities of being cured depending on the diagnosis and the medical action for a time span of at most 120 days.
Resource use and unit costs
When resources are used to provide medical care for one patient or to compensate for the production loss, they are unavailable for other uses. We included the costs of all those goods, services and inputs that may vary due to use of the different tests (variable costs). Table 3 gives an overview of the sources of these costs. Costs did not need to be discounted as we only studied a period of 120 days. Fig. 2 The first part of the decision tree for the hospital-based test. For each of the four medical strategies the rest of the tree structure is identical to the decision tree of the rapid test (Fig. 1 Hospital-based test, HmCap, sensitivity 0.94 [7] Hospital-based test HmCap, specificity 0.75 [7] Rapid test-helisal, sensitivity 0.84 [7] Rapid test-helisal, specificity 0.63 [7] Rapid test-immunocard, sensitivity 0.75 [7] Rapid test-immunocard, specificity 0.87 [7] If positive test, upper endoscopy 0.52 [9] If negative test, symptomatic treatment 0.58 [9] Upper endoscopy, sensitivity 1.00 See text
Upper endoscopy, specificity 1.00 See text
Our patient had paid employment and the opportunity cost was measured as ''production loss.' ' The costs of a visit to the GP and upper endoscopy included are the marginal costs and not the average costs. 3 
Results

Third key component: results of the cost-effectiveness analysis
To estimate the expected costs and dyspepsia-free days within a 120-day period, general principles of cost-effectiveness analysis are applied [11] . Table 4 shows that the hospital-based test is dominated by both the rapid tests even though the hospital-based test had higher sensitivity and specificity than Helisal (see Table 1 ). The reason for this is costs inferred by delay in (effective) treatment.
Immunocard versus Helisal has e26.35 lower cost and fewer dyspepsia-free days by 0.62. Therefore Helisal is cost-effective if the willingness to pay (WTP) for a dyspepsia-free day is more than e42.59 [the ICER-rate (incremental costs/incremental effect)]. Otherwise Immunocard is the preferred strategy since better specificity of this test is important in most relevant clinical situations, because the prevalence of ulcus is outweighed by the prevalence of NUD.
Fourth key component: sensitivity analyses
There are uncertainties in many parameters. The estimate of production loss varies according to the patient's work, and the costs of consultation and upper endoscopy depend on the length of the consultation and on the local routines at the medical clinic. Conclusions for cost and effect estimates were therefore tested by using one-way sensitivity analysis and Monte Carlo simulations.
First, one-way sensitivity analyses show that the results are very robust. There are no changes in the relative ranking of strategies (1. Immunocard; 2. Helisal; 3. hospital-based test) when 95% CIs of base case estimates are used ( Table 5) .
The 95% CI is taken from the medical literature in Tables 1, 2 . For the cost of consultation we used data from NOKLUS reports (unpublished) about the length of the consultations.
In addition, results are similar when changing the waiting time for upper endoscopy and delay of getting hospital-based test results. In general the costs decrease and the numbers of dyspepsia-free days increase when the level of diagnostic accuracy increases (percentage of true results), and when the probability of being cured increases.
Monte Carlo simulation in TreeAge recalculates cost effectiveness results by using a great number of assigned values randomly sampled from probability distributions, i.e., performs a probabilistic sensitivity analyses (PSA). In the simulation the parameters are assumed to be independent, and the effects of joint uncertainty across all parameters of the model are assessed. Thus we find the probability of one test being significantly cost-effective in terms of willingness to pay for each dyspepsia-free day. Because the unit costs are constrained to be positive, we used the gamma distribution to represent uncertainty for the cost parameters. Since probabilities are bounded by zero and one, we used the beta distribution to describe probabilities. 4 Figure 3 shows the probability that the different HP tests are significantly cost-effective at a 5% significance level depending on the WTP for each dyspepsia-free day. The acceptability curves are estimated from the proportion of times the test is preferred in 10,000 simulations. Helisal has greater health effect, and the proportion of Helisal being If NUD-cured after symptomatic treatment 0.70 [19, 20] If NUD-cured after triple therapy 0.70 [19, 20] If NUD-cured after endoscopy 0.85 [21, 4] If ulcer-cured after triple therapy 0.85 [22, 15] If ulcer-cured after 2nd triple therapy 0.955 [22, 15] If ulcer-cured after symptomatic treatment 0.50 [23, 24] Cost of visit to GP e20 a + production loss 0.4 day [26, 27] Cost of triple therapy e74 [28, 22] Cost of symptomatic treatment
Cost of upper endoscopy e160 a + production loss 1 day [26] a Includes cost of transport 3 The average cost of a consultation was e34.3 and an upper endoscopy cost e313.6. The marginal cost is based on a fixed fee schedule. In the average cost we include practice allowance from the municipalities to the general practice to cover fixed costs such as auxiliaries. The average cost for upper endoscopy includes 50% income from the State, independent of service to the patients. 4 More information about the gamma and the beta distribution in general is found in Spiegelhalter et al. [28] . cost-effective is increasing with WTP per dyspepsia free day, with curves intersecting for WTP = e45. Thus, results of the cost-effectiveness analysis are confirmed.
Discussion
There are several objections to the methods we have used. First, the survey is based on a questionnaire where the GP is assumed to have enough information to establish a preliminary diagnosis. When we composed the clinical vignette it was important to describe a realistic situation to get valid results. In the literature there have been discussions about the validity of written case scenarios in medical decision-making. One might say that by using a clinical vignette we measure competence (what a physician is capable of doing), and not performance (what a physician actually does in his day-to-day practice). Kuyvenhoven and co-workers [31] conclude that written simulations give a realistic impression of a GP's diagnostic and therapeutic approach to patients with vague symptoms like those in our clinical vignette. In a review of 74 published studies using written simulations, the validity issue was addressed in only 11 studies, and the conclusions were conflicting [32] . Peabody et al. [33] have validated clinical vignettes as a method for measuring the competence of physicians and the quality of their actual practice, and conclude that the quality of care can be measured by using clinical vignettes. Bias is more likely if the respondents feel obliged to dis- play some kind of expected behavior and/or if the written scenario differs from a typical situation. Our case history depicts a real patient with some minor modifications, in order to make the situation as realistic as possible, and Norwegian GPs are used to responding to clinical scenarios like these, making a realistic response probable. Second, the response rate was 57%, which may imply a selection bias the in results. Still, participants were similar to the total population of Norwegian GPs regarding age and sex, but fewer were on a fixed salary (14 vs. 28%) since the H. pylori test was more abundant among GPs on fee-forservice. If selection bias is present, we believe it would be reasonable to assume that participants are more knowledgeable of dyspepsia than non-responders, and therefore more likely to adhere to medical guidelines in this field.
Third, the outcome of the cost-effectiveness analysis has its weaknesses because we only include dyspepsia-free days after successful treatment. Many patients will be largely free of dyspepsia towards the end of the treatment period, particularly when treatment is symptomatic. We do not have pertinent information about this, and chose not to include any dyspepsia-free days during treatment.
Fourth, we chose to measure the opportunity costs for health care resources by marginal costs and not average costs. This can be discussed because short-term fixed costs are generally variable in the long term. However, in our analysis, the results are independent of whether we use average or marginal costs.
Fifth, we have used the production loss as an opportunity cost to the patient's time. Productivity cost has been studied by Jacob-Tacken et al. [34] , Severens et al. [35] and Koopmanschap et al. [36] . These studies have found that colleagues often undertake the absentees' work during normal working hours. Taking this and other compensating mechanisms into account, they find that only one-quarter of the productivity remained. The cost will depend on the slack or capacity utilization in the companies and the supply of labor. These studies were carried out in the Netherlands, and in view of a higher unemployment rate there, we believe the results are not so relevant in Norway. If the companies have slack or capacity to compensate for absence from work, this is a cost for the companies and the society as they have a larger work force than they need, and therefore we don't take this into account in our analysis. However, reducing the cost of production loss, the relative ranking of the strategies does not change.
Sixth, we find that the hospital-based test is dominated and Helisal is more cost-effective than Immunocard if WTP >e45. The WTP per dyspepsia-free day will vary over individuals and is difficult to measure. Because our patient is working and the production loss for a day was calculated to be e225, it seems reasonable to assume that decision-makers are willing to pay more than e45 per dyspepsia-free day.
Seventh, we assume that the GPs choose the same actions independent of using a rapid test or a hospital-based test. GPs receiving a delayed result may not use identical strategies and might not alter treatment after receiving an unexpected result. In the latter instance, this may incur greater costs due to delay of effective treatment.
Finally, In Fauli and Thue [37] we found that GPs having the test in general practice had a higher probability of using the test compared to those not having the test in office. Different use of tests will have an impact on which test is cost-effective, but this aspect is not included in our study.
Concluding remarks
We have developed a model that can be used to evaluate the cost-effectiveness of the diagnostic accuracy of tests, in particular laboratory analyses with substantial clinical impact. The main result is that rapid tests with lower sensitivity and specificity than the hospital-based test are costeffective because of the immediate laboratory result. Which rapid test is cost-effective depends on the willingness to pay for each dyspepsia-free day.
The policy implication of these results is that in deciding which test should be analyzed in GPs' offices, both the diagnostic accuracy of the test and the waiting time to receive the laboratory result should be considered. One may allow tests with somewhat inferior analytical quality in GPs office, if the waiting time to receive the result from an external laboratory delays the start of effective treatment.
In our future work we plan further studies on when it is cost effective to analyze laboratory tests in general practice.
